Trial Profile

A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Triheptanoin (Primary)
Indications Huntington's disease
Focus Therapeutic Use
Acronyms TRIHEP3

Most Recent Events

22 Sep 2021 Results from NCT02453061 and other study assessing association of triheptanoin with clinical stability (UHDRS) and decreased caudate atrophy in Huntington disease patients, presented at the 25th International Congress of Parkinson's Disease and Movement Disorders
24 Aug 2021 Status changed from active, no longer recruiting to completed.
20 Dec 2020 This trial has been completed in France, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com